Citations (37)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Fulvia Vascotto, Jutta Petschenka, Kerstin C. Walzer, Mathias Vormehr, Magdalena Brkic, Stefan Strobl, Roman Rösemann, Mustafa Diken, Sebastian Kreiter, Özlem Türeci & Ugur Sahin. (2019) Intravenous delivery of the toll-like receptor 7 agonist SC1 confers tumor control by inducing a CD8+ T cell response. OncoImmunology 8:7.
Read now
Read now
Mathias Vormehr, Katharina Reinhard, Renata Blatnik, Kathrin Josef, Jan David Beck, Nadja Salomon, Martin Suchan, Abderraouf Selmi, Fulvia Vascotto, Johannes Zerweck, Holger Wenschuh, Mustafa Diken, Sebastian Kreiter, Özlem Türeci, Angelika B. Riemer & Ugur Sahin. (2019) A non-functional neoepitope specific CD8+ T-cell response induced by tumor derived antigen exposure in vivo. OncoImmunology 8:3.
Read now
Read now
Gabriela Maria Wiedemann, Severin Johannes Jacobi, Michael Chaloupka, Angelina Krächan, Svetlana Hamm, Stefan Strobl, Roland Baumgartner, Simon Rothenfusser, Peter Duewell, Stefan Endres & Sebastian Kobold. (2016) A novel TLR7 agonist reverses NK cell anergy and cures RMA-S lymphoma-bearing mice. OncoImmunology 5:7.
Read now
Read now
Taylor J Brueseke & Krishnansu S Tewari. (2013) Toll-like receptor 8: augmentation of innate immunity in platinum resistant ovarian carcinoma. Clinical Pharmacology: Advances and Applications 5:sup1, pages 13-19.
Read now
Read now
Articles from other publishers (33)
Ying Chen, Siqun Zhou, Komal Pradhan, Natalia Chernyak, Esther Kofman, Fan Zhang, Sang Yeop Kim, Wolfgang Seghezzi, Aarron Willingham, W. Michael Seganish, Bhagyashree Bhagwat & Jin-Hwan Han. (2023) Development and application of an in vitro assay to assess target-independent B-cell activation by targeted TLR7 immune agonists. Journal of Immunological Methods 522, pages 113553.
Crossref
Crossref
Wenyue Zhang, Xiaodi Liu, Shuwen Cao, Qi Zhang, Xiaojiang Chen, Wanrong Luo, Jiabao Tan, Xiaolin Xu, Jing Tian, Phei Er Saw & Baoming Luo. (2023) Multifunctional Redox-Responsive Nanoplatform with Dual Activation of Macrophages and T Cells for Antitumor Immunotherapy. ACS Nano 17:15, pages 14424-14441.
Crossref
Crossref
Irene Veneziani, Claudia Alicata, Lorenzo Moretta & Enrico Maggi. (2022) The Latest Approach of Immunotherapy with Endosomal TLR Agonists Improving NK Cell Function: An Overview. Biomedicines 11:1, pages 64.
Crossref
Crossref
Deblin Jana, Bing He, Yun Chen, Jiawei Liu & Yanli Zhao. (2022) A Defect‐Engineered Nanozyme for Targeted NIR‐II Photothermal Immunotherapy of Cancer. Advanced Materials.
Crossref
Crossref
Christian Czysch, Carolina Medina‐Montano, Zifu Zhong, Alexander Fuchs, Judith Stickdorn, Pia Winterwerber, Sascha Schmitt, Kim Deswarte, Marco Raabe, Maximilian Scherger, Francis Combes, Jana De Vrieze, Sabah Kasmi, Niek N. Sandners, Stefan Lienenklaus, Kaloian Koynov, Hans‐Joachim Räder, Bart N. Lambrecht, Sunil A. David, Matthias Bros, Hansjörg Schild, Stephan Grabbe, Bruno G. De Geest & Lutz Nuhn. (2022) Transient Lymph Node Immune Activation by Hydrolysable Polycarbonate Nanogels. Advanced Functional Materials 32:35.
Crossref
Crossref
Peng Cheng, Peiliang Shen, Yunlong Shan, Yu Yang, Rui Deng, Wenxing Chen, Yin Lu & Zhonghong Wei. (2021) Gut Microbiota-Mediated Modulation of Cancer Progression and Therapy Efficacy. Frontiers in Cell and Developmental Biology 9.
Crossref
Crossref
Yuyan Jiang, Jiaguo Huang, Cheng Xu & Kanyi Pu. (2021) Activatable polymer nanoagonist for second near-infrared photothermal immunotherapy of cancer. Nature Communications 12:1.
Crossref
Crossref
Jingchao Li, Xiangrong Yu, Yuyan Jiang, Shasha He, Yan Zhang, Yu Luo & Kanyi Pu. (2020) Second Near‐Infrared Photothermal Semiconducting Polymer Nanoadjuvant for Enhanced Cancer Immunotherapy. Advanced Materials 33:4, pages 2003458.
Crossref
Crossref
Richard C. Walshaw, Jamie Honeychurch, Ananya Choudhury & Timothy M. Illidge. (2020) Toll-Like Receptor Agonists and Radiation Therapy Combinations: An Untapped Opportunity to Induce Anticancer Immunity and Improve Tumor control. International Journal of Radiation Oncology*Biology*Physics 108:1, pages 27-37.
Crossref
Crossref
Sandra Santos-Sierra. (2020) Developments in anticancer vaccination: budding new adjuvants. Biological Chemistry 401:4, pages 435-446.
Crossref
Crossref
Fusae Komura, Kana Okuzumi, Yuki Takahashi, Yoshinobu Takakura & Makiya Nishikawa. (2020) Development of RNA/DNA Hydrogel Targeting Toll-Like Receptor 7/8 for Sustained RNA Release and Potent Immune Activation. Molecules 25:3, pages 728.
Crossref
Crossref
Sumana Narayanan & Joseph J. Skitzki. 2020. Cancer Immunology. Cancer Immunology
363
378
.
Shweta Arora, Shaniya Ahmad, Rasha Irshad, Yamini Goyal, Sahar Rafat, Neha Siddiqui, Kapil Dev, Mohammad Husain, Shakir Ali, Anant Mohan & Mansoor Ali Syed. (2019) TLRs in pulmonary diseases. Life Sciences 233, pages 116671.
Crossref
Crossref
Thomas Szekely, Olivier Roy, Edith Dériaud, Aurélie Job, Richard Lo-Man, Claude Leclerc & Claude Taillefumier. (2018) Design, Synthesis, and Immunological Evaluation of a Multicomponent Construct Based on a Glycotripeptoid Core Comprising B and T Cell Epitopes and a Toll-like Receptor 7 Agonist That Elicits Potent Immune Responses. Journal of Medicinal Chemistry 61:21, pages 9568-9582.
Crossref
Crossref
Huju Chi, Chunman Li, Flora Sha Zhao, Li Zhang, Tzi Bun Ng, Guangyi Jin & Ou Sha. (2017) Anti-tumor Activity of Toll-Like Receptor 7 Agonists. Frontiers in Pharmacology 8.
Crossref
Crossref
Angela Tsai, Alivelu Irrinki, Jasmine Kaur, Tomas Cihlar, George Kukolj, Derek D. Sloan & Jeffrey P. Murry. (2017) Toll-Like Receptor 7 Agonist GS-9620 Induces HIV Expression and HIV-Specific Immunity in Cells from HIV-Infected Individuals on Suppressive Antiretroviral Therapy. Journal of Virology 91:8.
Crossref
Crossref
Jie Li, Heping Rao, Chang’e Jin & Jinrong Liu. (2017) Involvement of the Toll-Like Receptor/Nitric Oxide Signaling Pathway in the Pathogenesis of Cervical Cancer Caused by High-Risk Human Papillomavirus Infection. BioMed Research International 2017, pages 1-8.
Crossref
Crossref
Hilmar Weinmann. (2016) Cancer Immunotherapy: Selected Targets and Small-Molecule Modulators. ChemMedChem 11:5, pages 450-466.
Crossref
Crossref
Jiang Zhu, Shiping He, Jie Du, Zhulin Wang, Wang Li, Xianxiong Chen, Wenqi Jiang, Duo Zheng & Guangyi Jin. (2015) Local administration of a novel Toll-like receptor 7 agonist in combination with doxorubicin induces durable tumouricidal effects in a murine model of T cell lymphoma. Journal of Hematology & Oncology 8:1.
Crossref
Crossref
Guimiao Lin, Xiaomei Wang, Wanxian Yi, Chuanxia Zhang, Gaixia Xu, Xiaomei Zhu, Zhiming Cai, Yu Liu, Yuwen Diao, Marie Chia-Mi Lin & Guangyi Jin. (2015) A conjugate of octamer-binding transcription factor 4 and toll-like receptor 7 agonist prevents the growth and metastasis of testis embryonic carcinoma. Journal of Translational Medicine 13:1.
Crossref
Crossref
Hans-Heinrich Hoffmann, William M. Schneider & Charles M. Rice. (2015) Interferons and viruses: an evolutionary arms race of molecular interactions. Trends in Immunology 36:3, pages 124-138.
Crossref
Crossref
Julie A. Alosi, Scott W. Baldwin, Jacqueline Oxenberg & Joseph J. Skitzki. 2015. Cancer Immunology. Cancer Immunology
319
332
.
Zengguang Xu, Fengying Wu, Chunhong Wang, Xiyu Liu, Baoli Kang, Shan Shan, Xia Gu, Kailing Wang & Tao Ren. (2014) The stimulatory activity of plasma in patients with advanced non-small cell lung cancer requires TLR-stimulating nucleic acid immunoglobulin complexes and discriminates responsiveness to chemotherapy. Cancer Cell International 14:1.
Crossref
Crossref
Sebastian Kobold, Gabriela Wiedemann, Simon Rothenfußer & Stefan Endres. (2014) Modes of action of TLR7 agonists in cancer therapy. Immunotherapy 6:10, pages 1085-1095.
Crossref
Crossref
Donald W. Northfelt, Ramesh K. Ramanathan, Peter A. Cohen, Daniel D. Von Hoff, Glen J. Weiss, Gregory N. Dietsch, Kristi L. Manjarrez, Tressa D. Randall & Robert M. Hershberg. (2014) A Phase I Dose-Finding Study of the Novel Toll-like Receptor 8 Agonist VTX-2337 in Adult Subjects with Advanced Solid Tumors or Lymphoma. Clinical Cancer Research 20:14, pages 3683-3691.
Crossref
Crossref
Sara Harsini, Maani Beigy, Mahsa Akhavan-Sabbagh & Nima Rezaei. (2014) Toll-like receptors in lymphoid malignancies: Double-edged sword. Critical Reviews in Oncology/Hematology 89:2, pages 262-283.
Crossref
Crossref
Ryan M. Stephenson, Chwee Ming Lim, Maura Matthews, Gregory Dietsch, Robert Hershberg & Robert L. Ferris. (2013) TLR8 stimulation enhances cetuximab-mediated natural killer cell lysis of head and neck cancer cells and dendritic cell cross-priming of EGFR-specific CD8+ T cells. Cancer Immunology, Immunotherapy 62:8, pages 1347-1357.
Crossref
Crossref
Erina Koga‐Yamakawa, Simon J. Dovedi, Masashi Murata, Hiroyuki Matsui, Andrew J. Leishman, John Bell, Douglas Ferguson, Simon P. Heaton, Toshihiro Oki, Hideyuki Tomizawa, Ash Bahl, Haruo Takaku, Robert W. Wilkinson & Hideyuki Harada. (2012) Intratracheal and oral administration of SM‐276001: A selective TLR7 agonist, leads to antitumor efficacy in primary and metastatic models of cancer. International Journal of Cancer 132:3, pages 580-590.
Crossref
Crossref
Simon J. DovediMonique H. M. MelisRobert W. Wilkinson, Amy L. Adlard, Ian J. Stratford, Jamie HoneychurchTimothy M. Illidge. (2013) Systemic delivery of a TLR7 agonist in combination with radiation primes durable antitumor immune responses in mouse models of lymphoma. Blood 121:2, pages 251-259.
Crossref
Crossref
Holbrook E Kohrt, Roch Houot, Aurélien Marabelle, Hearn Jay Cho, Keren Osman, Matthew Goldstein, Ronald Levy & Joshua Brody. (2012) Combination strategies to enhance antitumor ADCC. Immunotherapy 4:5, pages 511-527.
Crossref
Crossref
Aldo Pinto, Silvana Morello & Rosalinda Sorrentino. (2011) Lung cancer and Toll-like receptors. Cancer Immunology, Immunotherapy 60:9, pages 1211-1220.
Crossref
Crossref
Ulrike Klier, Claudia Maletzki, Nadeshda Göttmann, Bernd Kreikemeyer & Michael Linnebacher. (2011) Avitalized bacteria mediate tumor growth control via activation of innate immunity. Cellular Immunology 269:2, pages 120-127.
Crossref
Crossref
Donald J. AbrahamJ. Ellis Bell & Jessica K. Bell. 2003. Burger's Medicinal Chemistry and Drug Discovery. Burger's Medicinal Chemistry and Drug Discovery
369
402
.